YUNG-SUNG YEH1,2,3, HSIANG-LIN TSAI4,5, YEN-CHENG CHEN4,6, WEI-CHIH SU4,6, PO-JUNG CHEN4,6, TSUNG-KUN CHANG4,6,7, CHING-CHUN LI4, CHING-WEN HUANG4,5, JAW-YUAN WANG4,5,6,8,9,10,*
Oncology Research, Vol.30, No.2, pp. 65-76, 2022, DOI:10.32604/or.2022.026659
- 05 January 2023
Abstract The controversial outcomes in patients with metastatic colorectal cancer (mCRC) highlight the need for developing effective systemic neoadjuvant treatment strategies to improve clinical results. The optimal treatment cycles in patients with mCRC for metastasectomy remain undefined. This retrospective study compared the efficacy, safety, and survival of cycles of neoadjuvant chemotherapy/targeted therapy for such patients. Sixty-four patients with mCRC who received neoadjuvant chemotherapy/targeted therapy following metastasectomy were enrolled between January 2018 and April 2022. Twenty-eight patients received 6 cycles of chemotherapy/targeted therapy, whereas 36 patients received ≥7 cycles (median, 13; range, 7–20). Clinical outcomes, including response,… More >
Login
Register
